Cathleen Phillips Davis
Geen lopende functies
Profiel
Cathleen Phillips Davis has been Vice President of Finance and Controller of Threshold Pharmaceuticals, Inc. since August 2006.
Previously, she was Controller of Threshold Pharmaceuticals from July 2005 to August 2006, Theravance, Inc. from 2002 to 2005 and ALZA Corporation from 1999 to 2002.
Ms. Davis received a BS degree in Business Administration from California State University, Hayward and became a Certified Public Accountant in 1993.
Eerdere bekende functies van Cathleen Phillips Davis
| Bedrijven | Functie | Einde |
|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Financieel Directeur/CFO | 02-11-2007 |
Opleiding van Cathleen Phillips Davis
| California State University-East Bay | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |